Skip to main content
. 2015 Dec 16;310(6):F466–F476. doi: 10.1152/ajprenal.00288.2015

Fig. 11.

Fig. 11.

Effect of the administration of AAV9(HO-1) on blood flow in the combined CKD-AVF model, assessed 2 wk after creation of the AVF. Assessment of blood flow through the AVF (AVF vein) and the contralateral carotid artery (CCA) was performed using a perivascular flow probe in mice, all of which were subjected to CKD and AVF and treated with either control AAV9(revHO-1) vector or AAV9(HO-1) vector. Determination of blood flow in the AVF vein and measurement of blood flow in the CCA were made as described in Fig. 2. n = 6 and n = 7 in AAV9(revHO-1) and AAV9(HO-1), respectively. *P < 0.05, AVF-AAV9(HO-1) vs. AVF-AAV9(revHO-1); †P < 0.05, CCA-AAV9(HO-1) vs. CCA-AAV9(revHO-1).